[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"trop2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:trop2":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,71,94,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100646924","phase-2-comparative-f-fdg-and-ga-my6349-petct-imaging-for-assessing-trop2-adc-therapeutic-efficacy-in-egfr-tki-resistant-advanced-nsclc-100646924",false,"NCT07685197","Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET\u002FCT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC","Efficacy Evaluation of TROP2 ADC Therapy in Patients With Advanced\u002FMetastatic NSCLC Resistant to EGFR-TKIs: A Comparative Imaging Study of ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET\u002FCT","Inclusion Criteria:\n\n* Aged ≥18 years at the time of signing the informed consent form, with no restriction on gender.\n* Histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC), classified as locally advanced Stage IIIB\u002FIIIC or metastatic Stage IV NSCLC (per the 8th edition of UICC\u002FAJCC TNM staging system for lung cancer), and not eligible for curative resection and\u002For definitive radiotherapy (with or without concurrent chemotherapy).\n* Presence of EGFR sensitizing mutations (exon 19 deletion or exon 21 L858R point mutation).\n* Subjects who have received first-line third-generation EGFR-TKI therapy with documented treatment failure. For subjects previously treated with third-generation EGFR-TKIs in adjuvant, neoadjuvant or consolidation settings, such TKI therapy will be regarded as first-line treatment for locally advanced or metastatic disease if disease progression occurs within ≤6 months after the last dose.\n* At least one measurable lesion as defined by RECIST v1.1; previously irradiated lesions shall not be selected as target lesions. Subjects with only cutaneous or osseous lesions are not eligible for enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to study drug administration.\n* Estimated life expectancy ≥12 weeks.\n* Adequate organ and bone marrow function (no blood transfusion, recombinant thrombopoietin or colony-stimulating factor administered within 2 weeks before dosing), defined as follows:\n\n  1. Hematology: Absolute neutrophil count (NEUT#) ≥1.5×10⁹\u002FL; platelets (PLT) ≥100×10⁹\u002FL; hemoglobin ≥90 g\u002FL.\n  2. Hepatic function: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN; total bilirubin (TBIL) ≤1.5×ULN; albumin ≥30 g\u002FL. For subjects with hepatic metastases at baseline, ALT and AST ≤5×ULN, TBIL ≤3×ULN.\n  3. Renal function: Creatinine clearance ≥50 mL\u002Fmin (calculated using the standard Cockcroft-Gault formula).\n  4. Coagulation function: International normalized ratio (INR), activated partial thromboplastin time (APTT) and prothrombin time (PT) ≤1.5×ULN.\n* Females of childbearing potential and male subjects whose partners are of childbearing potential must agree to use effective medical contraception from the date of informed consent signature through 6 months after the last study drug administration.\n* The subject voluntarily participates in this study, signs the informed consent form, and is able to comply with all protocol-specified visits and relevant procedures.\n\nExclusion Criteria:\n\n* Tumor histology or cytology confirms mixed components including small cell lung cancer, neuroendocrine carcinoma, carcinosarcoma, or squamous cell carcinoma.\n* Subjects with known leptomeningeal metastases, brainstem metastases, spinal cord metastases\u002Fcompression, or symptomatic unstable central nervous system (CNS) metastases are excluded unless they are off steroid therapy and maintain stable neurological status for at least two weeks after completion of definitive radiotherapy and steroid tapering.\n* Prior systemic anti-tumor therapy for locally advanced or metastatic non-squamous NSCLC other than third-generation EGFR-TKIs (e.g., chemotherapy, immunotherapy).\n* Previous treatment with any TROP2-targeted agents or therapeutics containing topoisomerase I inhibitors, including antibody-drug conjugates (ADCs), whether administered in adjuvant, neoadjuvant, or metastatic disease settings.\n* Thoracic radiotherapy with a cumulative dose \\>30 Gy delivered within 6 months prior to the first dose; non-thoracic or extended-field radiotherapy with a cumulative dose \\>30 Gy administered within 4 weeks prior to the first dose. Palliative radiotherapy for symptom control is permitted only if completed at least 2 weeks before study drug initiation.\n* History of another primary malignant tumor within 3 years before the first dose, excluding malignancies cured by local therapy such as basal cell carcinoma of the skin, cutaneous squamous cell carcinoma, and cervical carcinoma in situ.\n* Presence of any of the following cardiovascular or cerebrovascular diseases or risk factors:\n\n  1. Myocardial infarction, unstable angina, acute or persistent myocardial ischemia, New York Heart Association (NYHA) Class III\u002FIV heart failure, symptomatic or poorly controlled severe arrhythmia, cerebrovascular accident, transient ischemic attack, or other severe cardiovascular\u002Fcerebrovascular events within 6 months before dosing.\n  2. Medical history of myocarditis, primary cardiomyopathy, or specific cardiomyopathies.\n  3. Deep vein thrombosis, peripheral arterial thromboembolism, pulmonary embolism, or other severe thromboembolic events within 3 months prior to dosing (subjects may be enrolled if stably treated with low-molecular-weight heparin or equivalent anticoagulants for ≥2 weeks).\n  4. Life-threatening major vascular diseases including aortic aneurysm or aortic dissection requiring surgical intervention within 6 months before dosing.\n  5. Corrected QT interval (QTcF) \\>470 ms.\n* Uncontrolled systemic diseases as judged by the investigator:\n\n  1. Poorly controlled diabetes mellitus (two consecutive fasting blood glucose readings ≥10 mmol\u002FL).\n  2. Uncontrolled hypertension (systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg).\n  3. Clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once per week.\n* History of steroid-dependent non-infectious interstitial lung disease (ILD) or non-infectious pneumonitis; active ILD or non-infectious pneumonitis at screening; or suspicious ILD\u002Fpneumonitis that cannot be ruled out by screening imaging.\n* Documented severe dry eye syndrome, severe meibomian gland disease and\u002For blepharitis, or history of severe corneal disorders that hinder or delay corneal wound healing.\n* Clinically significant severe pulmonary impairment secondary to concurrent lung disorders, including but not limited to underlying lung diseases (e.g., severe asthma, advanced chronic obstructive pulmonary disease, restrictive lung disease within 3 months prior to dosing); autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement (rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.); or prior pneumonectomy.\n* Active chronic inflammatory bowel disease, gastrointestinal obstruction, severe ulceration, gastrointestinal perforation, intra-abdominal abscess, or acute gastrointestinal hemorrhage.\n* Active gastrointestinal disorders or other conditions that substantially alter the absorption, distribution, metabolism, or excretion of oral study drugs (e.g., refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow oral medication, history of extensive intestinal resection).\n* Risk of esophagotracheal or esophagopleural fistula; tumor invasion or compression of vital adjacent organs and vessels (heart, esophagus, superior vena cava, etc.) accompanied by relevant clinical manifestations such as superior vena cava syndrome.\n* Toxicities from prior anti-tumor therapy that have not resolved to Grade ≤1 per NCI CTCAE v5.0 or the thresholds specified in eligibility criteria (alopecia, fatigue, and other toxicities judged low-risk by the investigator are exempted).\n* Severe infection occurring within 4 weeks before dosing, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia; active infection requiring systemic antimicrobial therapy within 2 weeks before dosing.\n* Confirmed active pulmonary tuberculosis. Subjects with suspected active tuberculosis must undergo clinical examinations to rule out infection before enrollment.\n* Active hepatitis B (HBsAg-positive with HBV-DNA ≥500 IU\u002FmL or above the lower limit of quantification, whichever is higher); active hepatitis C (anti-HCV positive with HCV-RNA above the lower limit of quantification); or concurrent HBV and HCV co-infection.\n* Positive human immunodeficiency virus (HIV) serology or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.\n* History of allogeneic solid organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Major surgery performed within 4 weeks prior to dosing or major surgery planned during study participation.\n* Known hypersensitivity to the study drug or any of its excipients (including polysorbate 20); history of severe hypersensitivity reactions to other biologic agents.\n* Non-specific immunomodulatory therapy (including but not limited to interferon, IL-2) or proprietary Chinese medicines with approved anti-tumor indications administered within 2 weeks before dosing.\n* Current use (or inability to discontinue prior to the first study dose) of drugs or herbal supplements that are strong cytochrome P450 (CYP) 3A4 inducers, with a minimum 3-week washout period required. All subjects shall avoid concomitant use of any CYP3A4-inducing medications, herbal supplements, and\u002For relevant foods throughout the study.\n* Live vaccine administered within 30 days before dosing or planned live vaccination during study participation.\n* Rapid clinical deterioration during screening, such as marked decline in performance status.\n* Pregnant or breastfeeding women.\n* Local or systemic non-malignant diseases, or tumor-induced diseases\u002Fsymptoms that carry high medical risks and\u002For cause uncertainty in survival assessment, such as leukemoid reaction, cachexia, etc.\n* Any medical condition that, in the investigator's opinion, may confound the evaluation of the study drug, compromise subject safety, interfere with the interpretation of study results, or render the subject unsuitable for trial participation.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The primary objective is to evaluate the correlation between ⁶⁸Ga-MY6349 PET\u002FCT-derived metrics reflecting tumoral TROP2 expression activity (including SUVmax, SUVmean, MTV, TLG, etc.) and progression-free survival (PFS) assessed per RECIST v1.1. This study plans to enroll 100 EGFR-mutant patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance following first-line therapy with third-generation EGFR-TKIs.\n\nScreening assessments will be completed within 28 days after patients sign the informed consent form. Eligible subjects will undergo a baseline ⁶⁸Ga-MY6349 PET\u002FCT scan prior to study drug administration, with imaging coverage from mid-thighs to the vertex of the skull. All subjects will receive a ¹⁸F-FDG PET\u002FCT scan within 14 days after the ⁶⁸Ga-MY6349 PET\u002FCT. For patients who have undergone ¹⁸F-FDG PET\u002FCT within 14 days before the ⁶⁸Ga-MY6349 scan, the existing imaging data can be used for diagnostic performance evaluation, and repeat ¹⁸F-FDG PET\u002FCT is not required.\n\nSubsequently, subjects will receive monotherapy with sacituzumab govitecan at a dose of 5 mg\u002Fkg via intravenous infusion (IV) on Day 1 of each cycle, administered every 2 weeks (Q2W). Treatment will continue until investigator-confirmed radiological disease progression, intolerable adverse toxicity, voluntary treatment discontinuation by the subject, or any other protocol-specified treatment discontinuation criterion, whichever occurs first.\n\nAt 3 months after initiation of sacituzumab govitecan treatment, subjects will repeat the ⁶⁸Ga-MY6349 PET\u002FCT scan (coverage: mid-thighs to vertex), followed by a ¹⁸F-FDG PET\u002FCT examination within 14 days thereafter.\n\nEligible subjects will receive regular tumor assessments in accordance with RECIST v1.1. Within 48 weeks after the first dose, imaging-based tumor assessments will be performed every 6 weeks (±7 days). At Week 12 (±1 week), paired ⁶⁸Ga-MY6349 and ¹⁸F-FDG PET\u002FCT scans will be conducted without routine diagnostic CT. After Week 48, tumor assessments will be scheduled every 12 weeks (±7 days) until radiological disease progression, initiation of subsequent anti-tumor therapy, withdrawal of informed consent, loss to follow-up, death, or study termination by the sponsor, whichever comes first. Imaging assessments will follow the predetermined schedule regardless of dose delays or dose modifications.\n\nAfter the first documented complete response (CR) or partial response (PR), response confirmation imaging must be conducted no less than 4 weeks (28 days) later. For subjects discontinuing treatment for reasons other than radiological progression, death or loss to follow-up, if more than 4 weeks have passed since the last imaging evaluation, repeat imaging will be performed at the End-of-Treatment (EOT) visit. Subsequent imaging assessments will be conducted per schedule to the greatest extent feasible until radiological disease progression, initiation of new anti-tumor therapy, consent withdrawal, loss to follow-up, death, or sponsor-initiated study termination, whichever occurs earliest.\n\nAll ⁶⁸Ga-MY6349 PET\u002FCT images will be blindly and independently reviewed by two experienced nuclear medicine physicians who are not involved in this clinical trial (without access to any clinical data) to identify positive NSCLC lesions, as well as lesion location and count. In case of disagreement between the two independent readers regarding the presence of positive lesions, a blinded arbitration review by a senior nuclear medicine expert will be activated, and the arbitrator's reading results will serve as the final conclusion. All ¹⁸F-FDG PET\u002FCT images will undergo single blinded independent review by one nuclear medicine physician.\n\nUpon completion of treatment, all subjects will complete safety follow-up regardless of whether they receive subsequent anti-tumor therapy. Telephone-based survival follow-up visits will be conducted every 3 months (±14 days) after the last dose of study treatment to collect survival status and information on subsequent anti-tumor treatments, until subject withdrawal, loss to follow-up, death, or study closure, whichever occurs first.",[26,27,28,29,30],"NSCLC","EGFR Activating Mutation","EGFR-TKI-resistant Non-Small Cell Lung Cancer","Trop2","PET\u002FCT Imaging","NOT_YET_RECRUITING","2026-06-30",{"date":34,"type":35},"2026-07-06","ACTUAL",{"date":37,"type":20},"2026-07",{"date":39,"type":20},"2028-07",{"name":41,"class":42},"Zhou Chengzhi","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100612306","evaluation-of-trop-2-adc-in-breast-cancer-patients-with-brain-metastases-a-real-world-study-100612306","NCT07251868","Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study","Evaluation of Efficacy and Safety of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Multicenter Real-World Study","Inclusion Criteria:\n\n* At least 18 years old (based on actual age at the time of signing the informed consent form), with no restriction on gender\n* Able to understand the study purpose, risks, and benefits, and voluntarily sign the written informed consent form; if the patient has cognitive impairment or is unable to express themselves independently, their legal guardian\u002Fauthorized agent shall sign after being fully informed, and provide valid authorization documents.\n* Have access to complete medical records (including breast cancer primary lesion diagnosis data, brain metastasis diagnosis data, SG treatment records, follow-up data, etc.) in the study collaborating medical institutions\u002Fspecified medical systems to ensure traceability of treatment processes and outcomes.\n\nDiagnosed with breast cancer via histopathological\u002Fcytopathological examination, with the diagnostic report issued by a tertiary hospital or the study-designated pathology center.\n\n* Diagnosed with breast cancer brain metastasis based on meeting any of the following conditions: ① Definitive diagnosis by a physician with associate senior title or above, combining contrast-enhanced cranial magnetic resonance imaging (MRI)\u002Fcomputed tomography (CT) with clinical symptoms and signs; ② Postoperative pathology of brain metastatic lesions confirming breast cancer metastasis; ③ Pathological examination of brain metastatic lesion biopsy specimens confirming breast cancer metastasis.\n* No restrictions on the number, size of brain metastatic lesions, presence of meningeal metastasis, or presence of brain metastasis-related symptoms (e.g., headache, limb dysfunction).\n* Previous treatment with Sacituzumab Govitecan (SG), with clear medication records (prescription orders, medical orders, pharmacy dispensing records, etc.), and no restrictions on the line of SG treatment, dosage, or treatment cycles (both completion of full-cycle treatment and early discontinuation due to adverse reactions\u002Fprogression are acceptable).\n* No restriction on the start time of SG treatment ; patients currently receiving SG treatment, who have completed SG treatment, or who have discontinued SG treatment due to objective reasons are all eligible.\n* Stable vital signs at present, without the following uncontrolled severe conditions: ① Severe infections such as sepsis and severe pneumonia (symptoms relieved and laboratory indicators normalized after anti-infective treatment); ② Epileptic seizures within the past 3 months (or uncontrolled without standardized anti-epileptic treatment); ③ Failure of major organs such as heart, liver, and kidney (e.g., New York Heart Association (NYHA) Class Ⅳ cardiac function, Child-Pugh Class C liver function, chronic kidney disease Stage 5) .\n* The patient\u002Fguardian can cooperate with study follow-up (outpatient follow-up, telephone follow-up, electronic medical record extraction, etc.), and survival status, disease progression, subsequent treatment, adverse reactions, and other information can be obtained within the expected follow-up period.\n\nExclusion Criteria:\n\n* Complicated with other primary malignant tumors (excluding breast cancer), and the tumor was in an active stage within the past 5 years (not achieving complete remission or disease-free survival for more than 5 years).\n* Unable to cooperate with informed consent or follow-up due to mental illness, cognitive impairment, etc., and without qualified guardian assistance.\n* Concurrent participation in other interventional clinical trials (e.g., randomized controlled trials), which may affect data collection and result interpretation of this study.\n* Other conditions judged by the researcher to affect study quality or patient safety .",{"count":19,"type":20},"OBSERVATIONAL","The goal of this real-world study (RWS) is to evaluate the effectiveness of Trop-2 ADC (sacituzumab govitecan) in treating breast cancer patients with brain metastases, and to understand the safety profile of this drug in real clinical practice across multiple centers. The main questions it aims to answer are:\n\nDoes Trop-2 ADC (sacituzumab govitecan) improve intracranial outcomes in breast cancer patients with brain metastases (e.g., intracranial objective response rate, intracranial progression-free survival)? What types and rates of adverse events do breast cancer patients with brain metastases experience when receiving Trop-2 ADC (sacituzumab govitecan)? This is a multicenter real-world study, which will collect and analyze data from breast cancer patients with brain metastases who have received Trop-2 ADC (sacituzumab govitecan) in routine clinical care (no randomization or placebo control, consistent with real-world clinical scenarios).\n\nParticipants (breast cancer patients with brain metastases who received Trop-2 ADC) will have their data collected from:\n\nElectronic health records (EHRs) across multiple medical centers Regular clinical follow-up visits (e.g., once every 4-8 weeks) for imaging assessments (to evaluate brain metastasis changes) and safety monitoring Medical records documenting treatment responses, disease progression, and any adverse events during treatment and follow-up",[54,55,29],"Breast Cancer","Brain Metastases From Breast Cancer",[57,58,29,59],"breast cancer","Brain metastases","sacituzumab govitecan","RECRUITING","2025-11-24",{"date":63,"type":35},"2025-11-26",{"date":65,"type":35},"2024-08-01",{"date":67,"type":20},"2027-12-31",{"name":69,"class":42},"Peking University Cancer Hospital & Institute",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":70},"100604621","petct-for-trop2-adc-response-evaluation-nsclc-100604621","NCT07151898","PET\u002FCT for Trop2 ADC Response Evaluation NSCLC","Evaluation of Treatment Response to Trop2 ADC by 68Ga-MY6349 PET\u002FCT in NSCLC","Inclusion Criteria:\n\n* adult patients (aged 18 years or order)\n* histologically or cytologically confirmed metastatic NSCLC previously treated with systemic therapy, supported by imaging (e.g. CT, MRI), tumor markers, or pathology reports\n* presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1\n* willingness to undergo serial 68Ga-MY6349 PET\u002FCT scans before and during Trop2-ADC therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee\n\nExclusion Criteria:\n\n* Evidence of significantly impaired hepatic or renal function\n* Estimated life expectancy of less than 3 months",{"count":79,"type":20},50,"To evaluate whether serial 68Ga-MY6349 PET\u002FCT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in NSCLC patients.",[26,29,82],"PET\u002FCT",[26,29,82,84],"Trop2-ADC","2025-08-26",{"date":87,"type":35},"2025-09-03",{"date":89,"type":35},"2025-05-01",{"date":91,"type":20},"2027-05-01",{"name":93,"class":42},"The First Affiliated Hospital of Xiamen University",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":70},"100596533","68ga-my6349-petct-in-solid-tumors-100596533","NCT07046702","68Ga-MY6349 PET\u002FCT in Solid Tumors","68Ga-MY6349 PET\u002FCT in Solid Tumors and Compared With 18F-FDG PET\u002FCT","Inclusion Criteria:\n\n* adult patients (aged 18 years or older)\n* patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report)\n* patients who had scheduled both standard-of-care imaging and 68Ga-MY6349 PET\u002FCT scans\n* patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee\n\nExclusion Criteria:\n\n* patients with pregnancy\n* the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent",{"count":102,"type":20},300,"The objective of the study is to construct a noninvasive approach 68Ga-MY6349 PET\u002FCT to detect the Trop-2 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from Trop-2 PET\u002FCT.",[105,29,82],"Solid Tumor",[107,29,82],"Solid tumor","2025-07-14",{"date":110,"type":35},"2025-07-15",{"date":112,"type":35},"2024-12-10",{"date":114,"type":20},"2026-12-31",{"name":93,"class":42},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":123,"minAge":17,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":133,"locationsCount":70},"100596532","petct-for-trop2-adc-response-evaluation-cancers-100596532","NCT07046689","PET\u002FCT for Trop2 ADC Response Evaluation Cancers","Evaluation of Treatment Response to Trop2 ADC by 68Ga-MY6349 PET\u002FCT in Advanced Breast Cancer","Inclusion Criteria:\n\n* adult patients (aged 18 years or order)\n* histologically or cytologically confirmed metastatic breast cancer previously treated with systemic therapy, supported by imaging (e.g., MRI, CT), tumor markers, or pathology reports\n* presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1\n* willingness to undergo serial 68Ga-MY6349 PET\u002FCT scans before and during Trop2-ADC therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee\n\nExclusion Criteria:\n\n* Evidence of significantly impaired hepatic or renal function\n* Estimated life expectancy of less than 3 months","FEMALE",{"count":79,"type":20},"To evaluate whether serial 68Ga-MY6349 PET\u002FCT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in breast cancer patients.",[54,29,82],[128,29,82,84],"Breast cancer",{"date":110,"type":35},{"date":131,"type":35},"2024-11-01",{"date":114,"type":20},{"name":93,"class":42}]